Literature DB >> 18574676

Renal expression of adhesion molecules in anca-associated disease.

P Arrizabalaga1, M Solé, R Abellana, C Ascaso.   

Abstract

INTRODUCTION: Anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated disease among other manifestations can underlie rapidly progressive glomerulonephritis (RPGN), with crescentic and necrotizing GN. Differences in pathogenic immune mechanisms in RPGN may provide differences in the renal expression of adhesion molecules mediating these lesions.
METHODS: Renal intercellular adhesion molecule 1 (ICAM-1; CD54) and vascular cell adhesion molecule 1 (VCAM-1; CD106) were assessed in 40 patients with type I RPGN (anti-glomerular basement membrane antibodies, n = 4), type II (immune complexes, n = 17), and type III (ANCA, n = 19). Enzyme-linked immunosorbent assay (ELISA) for detection of immunoglobulin G antibodies against the Goodpasture's antigen and indirect immunofluorescence and ELISA for myeloperoxidase (MPO) and proteinase 3 (PR3) were performed for ANCA testing. Ten normal renal tissues were used as controls. Relationships between ICAM-1 and VCAM-1, histopathologic features, and CD18, CD14, and CD3 cells were analyzed.
RESULTS: Abnormal ICAM-1 and VCAM-1 in tubule was seen in >80% of biopsies with RPGN. Abnormal VCAM-1 in glomerular tuft was seen in >60% of biopsies with RPGN. Glomerular ICAM-1 was associated with less glomerulosclerosis (chi (2) = 6.719, p = 0.01), less interstitial fibrosis (chi (2) = 4.322, p < 0.05), and less tubular atrophy (chi (2) = 8.547, p < 0.005). Glomerular VCAM-1 was associated with glomerular leukocyte infiltration (chi (2) = 4.698, p < 0.05). Glomerular tuft stains of ++/+++ for VCAM-1 was observed in 10% from MPO-ANCA-GN patients but in 60% from PR3-ANCA-GN (Fi = 8.538, p = 0.03).
CONCLUSIONS: The following conclusions can be made from this study. (1) The renal expression of ICAM-1 and VCAM-1 is upregulated in RPGN, and this is associated with the histological activity. (2) De novo expression of VCAM-1 on glomerular tuft suggests that endothelial cells play a role in RPGN. (3) De novo tubular expression of ICAM-1 and VCAM-1 suggests that epithelial cells may participate in adhesive interactions in RPGN. (4) De novo expression of VCAM-1 at the glomerular tuft in PR3-ANCA positive patients seems greater than in MPO-ANCA positive patients, which suggests that testing specific immune activation mechanisms may play a role in ANCA-associated GN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574676     DOI: 10.1007/s10875-008-9215-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  24 in total

Review 1.  Cell adhesion molecules and the glomerulopathies.

Authors:  S Adler; H R Brady
Journal:  Am J Med       Date:  1999-10       Impact factor: 4.965

2.  Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups.

Authors:  Herbert A Hauer; Ingeborg M Bajema; Hans C van Houwelingen; Franco Ferrario; Laure-Hélène Noël; Rüdiger Waldherr; David R W Jayne; Niels Rasmussen; Jan A Bruijn; E Christiaan Hagen
Journal:  Kidney Int       Date:  2002-01       Impact factor: 10.612

Review 3.  Histopathological atlas of renal diseases: ANCA-associated vasculitis (first part).

Authors:  Franco Ferrario; Maria Pia Rastaldi
Journal:  J Nephrol       Date:  2005 Mar-Apr       Impact factor: 3.902

4.  Adhesion molecule interactions in human glomerulonephritis: importance of the tubulointerstitium.

Authors:  P Roy-Chaudhury; B Wu; G King; M Campbell; A M Macleod; N E Haites; J G Simpson; D A Power
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

Review 5.  Histopathological atlas of renal diseases: ANCA-associated vasculitis (Second part).

Authors:  Franco Ferrario; Maria Pia Rastaldi
Journal:  J Nephrol       Date:  2005 May-Jun       Impact factor: 3.902

6.  Anti-myeloperoxidase antibodies enhance phagocytosis, IL-8 production, and glucose uptake of polymorphonuclear neutrophils rather than anti-proteinase 3 antibodies leading to activation-induced cell death of the neutrophils.

Authors:  S C Hsieh; H S Yu; S H Cheng; K J Li; M C Lu; C H Wu; C Y Tsai; C L Yu
Journal:  Clin Rheumatol       Date:  2006-03-31       Impact factor: 2.980

7.  Glomerular vascular cell adhesion molecule-1 expression in renal vasculitis.

Authors:  A A Pall; A J Howie; D Adu; G M Richards; C D Inward; D V Milford; N T Richards; J Michael; C M Taylor
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

8.  Costimulatory molecules CD80 and CD86 in human crescentic glomerulonephritis.

Authors:  Qiong Wu; Kiichiro Jinde; Masayuki Endoh; Hideto Sakai
Journal:  Am J Kidney Dis       Date:  2003-05       Impact factor: 8.860

9.  Tubular and interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy.

Authors:  Pilar Arrizabalaga; Manel Solé; Rosa Abellana; Xavier de las Cuevas; Josep Soler; Jordi Pascual; Carlos Ascaso
Journal:  Am J Nephrol       Date:  2003-01-24       Impact factor: 3.754

10.  VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis.

Authors:  P A Bacon; R J Moots; A Exley; R Luqmani; N Rasmussen
Journal:  Clin Exp Rheumatol       Date:  1995 Mar-Apr       Impact factor: 4.473

View more
  3 in total

Review 1.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

2.  In situ evidence of pulmonary endothelial activation in patients with granulomatosis with polyangiitis and systemic sclerosis.

Authors:  Leticia Kawano-Dourado; Alexandre M Ab'Saber; Vera Luiza Capelozzi; Carla Valeri; Carmen Sílvia Valente Barbas
Journal:  Lung       Date:  2015-03-19       Impact factor: 2.584

3.  Gene Expression Pathways across Multiple Tissues in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Reveal Core Pathways of Disease Pathology.

Authors:  Marcia A Friedman; Dongseok Choi; Stephen R Planck; James T Rosenbaum; Cailin H Sibley
Journal:  J Rheumatol       Date:  2019-01-15       Impact factor: 4.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.